ECHELON-2: 5-Year Results of Brentuximab Vedotin + Chemotherapy for CD30+ Peripheral T-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology